Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity

Journal of Investigative Dermatology

Volumn 133, Issue 5, 2013, Pages 1340-1350

  Syed, Farhatullah ^a,b   Sanganee, Hitesh J ^c   Bahl, Ashwani ^c   Bayat, Ardeshir ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AZD 8055; CELL MARKER; DERMATOLOGICAL AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KU 0063794; KU 0068650; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; PROTEIN P70; PROTEIN P70 S6K; RAPAMYCIN; SERINE; THREONINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIKELOID SCAR ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SPREADING; COMPARATIVE EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; INFLAMMATORY CELL; KELOID; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; TISSUE STRUCTURE; UPREGULATION;

EID: 84876667562     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.483     Document Type: Article

References (35)

1. Bagabir R, Syed F, Paus R et al. (2012) Long-term organ culture of keloid disease tissue. Exp Dermatol 21:376-81
2. Benjamin D, Colombi M, Moroni C et al. (2011) Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10:868-80
3. Bracho-Valdes I, Moreno-Alvarez P, Valencia-Martienz I et al. (2011) mTORC1-and mTORC2-interacting proteins keep their multifunctional partners focused. IUBMB Life 63:896-914
4. Chapuis N, Tamburini J, Green AS et al. (2010) Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16:5424-35
5. Chresta CM, Davies BR, Hickson I et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70:288-98
6. Dazert E, Hall MN (2011) mTOR signaling in disease. Curr Opin Cell Biol 23:744-55
7. Dormond-Meuwly A, Roulin D, Dufour M et al. (2011) The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors. Biochem Biophys Res Commun 407:714-9
8. Garcia-Martinez JM, Moran J, Clarke RG et al. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421:29-42
9. Jacinto E, Loewith R, Schmidt A et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122-8
10. Janes MR, Limon JJ, So L et al. (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16:205-13
11. Jorge LJ, David S (2011) Potential therapeutic roles for inhibition of the PI3K/Akt/mTOR pathway in the pathophysiology of diabetic retinopathy. J Ophthalmol 2011. doi:10.1155/2011/589813
12. Lewis GP, Chapin EA, Byun J et al. (2009) Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. Invest Ophthalmol Vis Sci 50:4429-35
13. Lim IJ, Phan TT, Tan EK et al. (2003) Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloids. J Biol Chem 278:40851-8
14. Malagu K, Duggan H, Menear K et al. (2009) The discovery and optimisation of pyrido [2, 3-d] pyrimidine-2, 4-diamines as potent and selective inhibitors of mTOR kinase. Bioorg Med Chem Lett 19:5950-3
15. Mall JW, Pollmann C, Muller JM et al. (2002) [Keloid of the earlobe after ear piercing. Not only a surgical problem]. Chirurg 73:514-6
16. Marshall G, Howard Z, Dry J et al. (2011) Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. Biochem Soc Trans 39:456-9
17. Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797-803
18. Ong CT, Khoo YT, Mukhopadhyay A et al. (2007) mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol 16:394-404
19. Patel NP, Lawrence Cervino A (2010) Keloid treatment: is there a role for acellular human dermis (Alloderm)? J Plast Reconstr Aesthet Surg 63:1344-8
20. Santiskulvong C, Konecny GE, Fekete M et al. (2011) Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 17:2373-84
21. Shegogue D, Trojanowska M (2004) Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 279:23166-75
22. Shih B, Garside E, McGrouther DA et al. (2010) Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair Regen 18:139-53
23. Sini P, James D, Chresta C et al. (2010) Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy 6:553-4
24. Sparks CA, Guertin DA (2010) Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29:3733-44
25. Syed F, Ahmadi E, IqbalSAetal. (2011) Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol 164:83-96
26. Syed F, Bayat A (2012a) Notch signalling pathway in keloid disease: Enhanced fibroblast activity in a Jagged-1 peptide dependent manner in lesional versus extra-lesional fibroblasts. Wound Repair Regen 20: 688-706
27. Syed F, Bayat A (2012b) Superior effect of combination versus single steroid therapy in keloid disease: a comparative in vitro analysis of glucocorticoids. Wound Repair Regen doi:10.1111/j.1524-475X.2012.00862.x
28. Syed F, Sherris D, Paus R et al. (2012a) Keloid disease can be inhibited by antagonizing excessive mTOR signalling with a novel dual TORC1/2 inhibitor. Am J Pathol 181:1642-58
29. Syed F, Thomas A, Singh S et al. (2012b) In vitro study of novel collagenase (Xiaflexs) on Dupuytren's disease fibroblasts displays unique drug related properties. PloS One 7:e31430
30. Vincent AS, Phan TT, Mukhopadhyay A et al. (2007) Human skin keloid fibroblasts display bioenergetics of cancer cells. J Invest Dermatol 128:702-9
31. Willems L, Chapuis N, Puissant A et al. (2012) The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 26:1195-202
32. Xing JZ, Zhu L, Jackson JA et al. (2005) Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 18:154-61
33. Xue Q, Hopkins B, Perruzzi C et al. (2008) Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 68:9551
34. Yu K, Shi C, Toral-Barza L et al. (2010) Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 70:621
35. Zhang Q, Kelly AP, Wang L et al. (2006) Green tea extract and ( -)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/Akt signaling pathways. J Invest Dermatol 126:2607-13